First Manhattan’s ADC Therapeutics ADCT Stock Holding History

First Manhattan’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200	Closed	–	–	1682
2022 Q3	$0	Hold	200	–	–	﹤0.01%	1502
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	1459
2022 Q1	$2K	Hold	200	–	–	﹤0.01%	1472
2021 Q4	$4K	Hold	200	–	–	﹤0.01%	1391
2021 Q3	$5K	Hold	200	–	–	﹤0.01%	1376
2021 Q2	$4K	Hold	200	–	–	﹤0.01%	1416
2021 Q1	$4K	Buy	+200	New	+$5.79K	﹤0.01%	1362

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Manhattan's ADCT Position: Q4 2022 in Review

First Manhattan sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 200 shares.

First Manhattan first reported a position in ADCT in Q1 2021 and held it in 7 quarters. The position peaked at $5K in Q3 2021. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

First Manhattan reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 200 ADC Therapeutics shares in Q4 2022.
First Manhattan first reported a position in ADC Therapeutics in Q1 2021 and held it in 7 quarters.
First Manhattan's ADC Therapeutics position peaked at $5K in Q3 2021.
60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.